Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) have been assigned an average recommendation of “Hold” from the twenty-one analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $52.67.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. Bank of America Corporation reduced their price target on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 4th. Canaccord Genuity reissued a “buy” rating and set a $44.00 price target (down previously from $48.00) on shares of Pacira Pharmaceuticals in a research report on Sunday, October 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Pacira Pharmaceuticals in a research report on Thursday, September 28th. They set a “neutral” rating and a $41.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Tuesday, September 26th.

WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/11/pacira-pharmaceuticals-inc-pcrx-receives-consensus-rating-of-hold-from-analysts.html.

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 34.95 on Wednesday. Pacira Pharmaceuticals has a 52 week low of $29.95 and a 52 week high of $58.95. The stock’s market cap is $1.41 billion. The stock has a 50 day moving average price of $36.97 and a 200-day moving average price of $43.10.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). The firm had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. Pacira Pharmaceuticals’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $0.21 EPS. On average, equities analysts anticipate that Pacira Pharmaceuticals will post ($0.18) EPS for the current fiscal year.

In other news, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the transaction, the chief accounting officer now owns 21,312 shares in the company, valued at approximately $783,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now owns 3,518 shares in the company, valued at approximately $127,175.70. The disclosure for this sale can be found here. Insiders have sold a total of 33,390 shares of company stock worth $1,215,480 in the last quarter. Corporate insiders own 6.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Pacira Pharmaceuticals by 9.2% during the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock worth $165,914,000 after acquiring an additional 294,494 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Pacira Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock worth $146,538,000 after acquiring an additional 211,982 shares during the last quarter. HealthCor Management L.P. boosted its stake in shares of Pacira Pharmaceuticals by 63.1% during the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after acquiring an additional 693,799 shares during the last quarter. State Street Corp boosted its stake in shares of Pacira Pharmaceuticals by 1.0% during the 2nd quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after acquiring an additional 10,727 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Pacira Pharmaceuticals by 1.6% during the 2nd quarter. Macquarie Group Ltd. now owns 1,091,530 shares of the company’s stock worth $52,066,000 after acquiring an additional 16,760 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.